REGENXBIO Inc. (RGNX): Cash & Equivalents

Annual figures by period end, from SEC filings.

$34.47M
As of 2025-12-31
$36.49M
As of 2026-06-30
-29.2%
3-year compound annual growth
-36.7%
5-year compound annual growth
-4.4%
10-year compound annual growth
$345.21M2013-12-31: $1.12M2014-12-31: $1.12M2015-12-31: $54.12M2016-12-31: $24.84M2017-12-31: $46.66M2018-12-31: $75.56M2019-12-31: $69.51M2020-12-31: $338.43M2021-12-31: $345.21M2022-12-31: $96.95M2023-12-31: $34.52M2024-12-31: $57.53M2025-12-31: $34.47M$34.47M
2013-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$34.47M-40.1%2026-03-05, Balance as of period end
2024-12-31$57.53M+66.6%2026-03-05, Balance as of period end
2023-12-31$34.52M-64.4%2025-03-13, Balance as of period end
2022-12-31$96.95M-71.9%2025-03-13, Balance as of period end
2021-12-31$345.21M+2.0%2024-02-27, Balance as of period end
2020-12-31$338.43M+386.8%2023-02-28, Balance as of period end
2019-12-31$69.51M-8.0%2022-03-01, Balance as of period end
2018-12-31$75.56M+62.0%2021-03-01, Balance as of period end
2017-12-31$46.66M+87.8%2020-02-26, Balance as of period end
2016-12-31$24.84M-54.1%2019-02-27, Balance as of period end
2015-12-31$54.12Mn/m2018-03-06, Balance as of period end
2014-12-31$1.12M+0.2%2017-03-07, Balance as of period end
2013-12-31$1.12Mn/a2016-03-03, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
REGENXBIO Inc. (RGNX)2025-12-31$34.47M-40.1%
Ginkgo Bioworks Holdings, Inc. (DNA)2025-12-31$167.20M-70.2%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$91.14M-36.7%
Beam Therapeutics Inc. (BEAM)2025-12-31$294.94M+4.6%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$129.88M-42.1%
Atara Biotherapeutics, Inc. (ATRA)2025-12-31$8.48M-66.1%
Agenus Inc (AGEN)2025-12-31$3.00M-92.6%
ImmunityBio, Inc. (IBRX)2025-12-31$88.33M-38.4%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$163.08M+41.0%

Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗